This study was performed to assess the influence of age, sex, smoking, and contraceptive use on CYP2A6 activity. In the metabolism of caffeine, the conversion of 1,7 dimethylxanthine (17X) to 1,7 dimethiylurate (17U) is catalyzed primarily by CYP2A6. CYP2A6 phenotype was determined by the urinary ratio 17U:17X in the interval of 4–5 h after caffeine intake in 179 healthy white Spaniards (102 women and 76 men). There were 99 non-smokers and 80 smokers. Among women, 26 were taking oral contraceptives. The age was the most important predictive factor of CYP2A6 activity (P < 0.001) with older subjects having higher activity. The influence of the gender was more modest (P = 0.07) with women exhibiting borderline increased values of the CYP2A6 marker than men. Tobacco smoking did not affect CYP2A6 activity. However, the CYP2A6 marker resulted to be strongly related to the use of oral contraceptives. The women users of oral contraceptives had higher values of CYP2A6 marker than both women not taking oral contraceptives and men (P < 0.001 in both comparisons). The results indicate that age, oral contraceptive use, and possibly gender should be controlled in epidemiological studies dealing with CYP2A6 activity and its relationship with xenobiotics exposure and genetic or pathological factor.
1 Koskela S Hakkola J Hukkanen J Pelkonen O Sorri M Saranen A . Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol1999; 57: 1407–1413.
2.
2 Maurice M Emiliani S Dalet-Beluche I Derancourt J Lange R . Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem1991; 200: 511–517.
3.
3 Yun C Shimada T Guengerich FP . Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol1991; 40: 679–685.
4.
4 Shimada T Yamazaki H Mimura M Inui Y Guengerich FP . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther1994; 270: 414–423.
5.
5 Pelkonen O Rautio A Raunio H Pasanen M . CYP2A6: a human coumarin 7-hydroxylase. Toxicology2000; 144: 139–147.
6.
6 Raunio H Syngelmä T Pasanen M Juvonen R Honkakoski P Kairaluoma MA . Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem Pharmacol1988; 37: 3889–3895.
7.
7 Nakajima M Yamamoto T Nunoya K Yokoi T Nagashima K Inoue K . Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos1996; 24: 1212–1217.
8.
8 Nakajima M Yamamoto T Nunoya K Yokoi T Nagashima K Inoue K . Characterization of CYP2A6 involved in 3-hydroxylation of cotinine in humans liver microsomes. J Pharmacol Exp Ther1996; 277: 1010–1015.
9.
9 Lewis DF Lake BG Dickins M Goldfarb PS . Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template. Enzyme-substrate interactions and QSARs for binding affinity and inhibition. Toxicol In Vitro2003; 17: 179–190.
10.
10 Rautio A . Polymorphic CYP2A6 and its clinical and toxicological significance. Pharmacogenomics J2003; 3: 5–7.
11.
11 Aoyama T Yamano S Guzelian PS Gelboin HV Gonzalez FJ . Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci U S A1990; 87: 4790–4793.
12.
12 Crespi CL Penman BW Leakey JA Arlotto MP Stark A Parkinson A . Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis1990; 11: 1293–1300.
13.
13 Yamazaki H Inui Y Yun CH Guengerich FP Shimada T . Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis1992; 13: 1789–1794.
14.
14 Camus AM Geneste O Honkakoski P Béréziat JC Henderson CJ Wolf CR . High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog1993; 7: 268–275.
15.
15 Pianezza ML Sellers EM Tyndale RF . Nicotine metabolism defect reduces smoking. Lancet1999; 353: 898–899.
16.
16 Miyamoto M Umetsu Y Dosaka-Akita H Sawamura Y Yokota J Kunitoh H . CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun1999; 261: 658–660.
17.
17 Topcu Z . CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis2002; 23: 595–598.
18.
18 Schoedel KA Hoffmann EB Rao Y Sellers EM Tyndale RF . Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics2004; 14: 615–626.
19.
19 Xu P Huang SL Zhu RH Han XM Zhou HH . Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Eur J Clin Pharmacol2002; 58: 333–337.
20.
20 Kimura M Yamazaki H Fujieda M Kiyotani K Honda G Saruwatari J . CYP2A6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos2005; 33: 1361–1366.
21.
21 Bechtel YC Haffen E Lelouët H Brientini MP Paintaud G Miguet JP . Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients. Int J Clin Pharmacol Ther2000; 38: 467–475.
22.
22 Bechtel YC Lelouët H Brientini MP David-Laroche M Miguet JP Paintaud G . Caffeine metabolism differences in acute hepatitis of viral and drug origin. Therapie2000; 55: 619–627.
23.
23 Lelouet H Bechtel YC Paintaud G Brientini MP Miguet JP Bechtel PR . Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. Int J Clin Pharmacol Ther2001; 39: 25–32.
24.
24 Nowell S Sweeney C Hammons G Kadlubar FF Lang NP . CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev2002; 11: 377–383.
25.
25 Grant DM Tand BK Kalow W . Variability in caffeine metabolism. Clin Pharmacol Ther1983; 33: 591–602.
26.
26 Gu L Gonzalez FJ Kalow W Tang BK . Biotransformation of caffeine paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics1992; 2: 73–77.
27.
27 Rautio A Kraul H Kojo A Salmela E Pelkonen O . Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics1992; 2: 227–233.
28.
28 Sinues B Sáenz MA Lanuza J Bernal ML Fanlo A Juste JL . Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev1999; 8: 159–166.
29.
29 Molander L Lunell E . Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol2001; 56: 813–819.
30.
30 Parkinson A Mudra DR Johnson C Dwyer A Carroll KM . The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol2004; 199: 193–209.
31.
31 Sotaniemi EA Lumme P Arvela P Rautio A . Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. Therapie1996; 51: 363–366.
32.
32 Benowitz NL Swan GE Lessov CN Jacob P . Oral contraceptives induce CYP2A6 activity and accelerate nicotine metabolism. Clin Pharmacol Ther2004; 75: 36 [abstract].
33.
33 Zeman MV Hiraki L Sellers EM . Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. J Womens Health Gend Based Med2002; 11: 147–153.
34.
34 Nakajima M Fukami T Yamanaka H Higashi E Sakai H Yoshida R . Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther2006; 80: 282–297.
35.
35 Lete I Bermejo R Coll C Dueñas JL Doval JL Martínez-Salmeán J . Use of contraceptive methods in Spain: results of a national survey. Contraception2001; 63: 235–238.
36.
36 Dempsey D Jacob P Benowitz NL . Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther2002; 301: 594–598.
37.
37 Benowitz NL Lessov-Schlaggar CN Swan GE Jacob P . Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther2006; 79: 480–488.
38.
38 Balogh A Klinger G Henschel L Börner A Vollanth R Kuhnz W . Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol1995; 48: 161–166.
39.
39 Slayter KL Ludwig EA Lew KH Middleton E Ferry JJ Jusko WJ . Oral contraceptives effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther1996; 59: 312–321.
40.
40 Laine K Tybring G Bertilsson L . No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured in healthy Swedish white subjects. Clin Pharmacol Ther2000; 68: 151–159.
41.
41 Higashi E Nakajima M Katoh M Tokudome S Yokoi T . Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos2007; 35: 508–514.
42.
42 Stoehr GP Kroboth PD Juhl RP Wender DB Phillips JP Smith RB . Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther1984; 36: 683–690.
43.
43 Miners JO Grgurinovich N Whitehead AG Robson RA Birkett DJ . Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetyl-salicylic acid. Br J Clin Pharmacol1986; 22: 135–142.
44.
44 Pianezza ML Sellers EM Tyndale RF . Nicotine metabolism defect reduces smoking. Nature1998; 393: 750.
45.
45 London SJ Idle JR Daly AK Coetzze GA . Genetic variation of CYP2A6, smoking and risk of cancer. Lancet1999; 353: 898–899.
46.
46 Rao Y Hoffmann E Zia M Bodin L Zeman M Sellers EM . Duplications and defects in the CYP2A6 gene: identification, genotyping and in vivo effects on smoking. Mol Pharmacol2000; 58: 747–755.
